# Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

> **NCT02595970** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT02595970
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-20
- **Primary completion:** 2017-02-09
- **Final completion:** 2017-02-09
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595970, "Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02595970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*